RxDoctor Payments Data

Musaid Khan, MD

Neurology · Charlotte, NCNPI 1134263460

Payments from drug & device makers

$5,620in general payments, 2019–2025

Across 234 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$431
  • Neurelis, Inc.$293
  • Biogen$192
  • SK Life Science, Inc.$168
  • TG Therapeutics, Inc.$144
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$1,81032%
  • Food & beverage$3,78367%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,620 in reported general payments places this provider in the 65th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$111,248
Medicare patients
270
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate15$149,291
Nurtec OdtRimegepant Sulfate72$124,163
RexultiBrexpiprazole74$111,000
Avonex Pen (4 Pack)Interferon Beta-1a12$99,369
GlatopaGlatiramer Acetate28$65,229
OxycontinOxycodone Hcl16$51,231
QuliptaAtogepant16$17,541
BriviactBrivaracetam12$16,028
VimpatLacosamide12$14,623
Memantine Hcl536$12,577
UbrelvyUbrogepant11$10,161
FingolimodFingolimod Hcl12$6,868
Gabapentin666$6,268
Donepezil Hcl833$5,397
Levetiracetam260$4,249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$192$149,29115 claims
PfizerNurtec Odt$431$124,16372 claims
Otsuka America Pharmaceutical, Inc.Rexulti$101$111,00074 claims
UCB, Inc.Briviact, Vimpat$136$30,65124 claims
AbbVieQulipta, Ubrelvy$3,049$27,70227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 566 neurology providers in North Carolina.

Other neurology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →